

A monoclonal anti-thromboxane B₂ antibody

Margot Reinke and Kay Brune

Department of Pharmacology, University of Erlangen-Nürnberg, Universitätsstrasse 22, D-8520 Erlangen, FRG

Received 9 March 1988

A monoclonal antibody against thromboxane B₂ which may be used in standard fluid phase radioimmunoassays with a detection limit of around 40 pg and a binding affinity of $1.98 \times 10^9 \text{ M}^{-1}$ is described. Limited crossreactivity could be observed only with structurally closely related compounds such as 2,3-dinor-thromboxane B₂ (8.9%), thromboxane B₁ (15.7%) and thromboxane B₃ (39.7%). Detectable crossreactivity with 11-dehydro-thromboxane B₂, ω -carboxy-thromboxane B₂, ω -hydroxy-thromboxane B₂, prostaglandins of the D-, E- and F-type as well as metabolites of prostacyclin was lacking. The monoclonal anti-thromboxane B₂ antibody proved well suited for measuring the thromboxane B₂ content in tissue culture supernatants as well as in human serum.

Thromboxane B₂; Monoclonal antibody; Radioimmunoassay

1. INTRODUCTION

Thromboxanes (TXs) comprise a distinct subclass of eicosanoids known to derive from platelets and to regulate the function of these blood particles. The biologically active TXA₂ causes platelet aggregation and may play an important role in acute coronary disease [1]. Measurements of TXs have also attained clinical importance for monitoring graft rejection following kidney transplantation [2]. However, TXA₂ is very unstable, with a half-life of 30–40 s at 37°C and physiological pH [3], and is quickly metabolized into the inactive but stable TXB₂. Therefore TXB₂ is widely used for indirect measurements of TXA₂ production in biological samples.

Many sensitive radioimmunoassays (RIAs) have been developed using polyclonal antibodies (PABs) from rabbit immunized with TXB₂. These PABs are very sensitive in this system and show little crossreaction with most prostaglandins, but, when tested, have been less specific against TXB₂ metabolites. Many PABs show considerable

crossreaction with 2,3-dinor-TXB₂, which is present in blood [4,5], and, in even larger amounts, in urine [5,6].

Monoclonal antibodies (MABs) have been produced against prostaglandin E₂ [7–9], and can show good sensitivity and high specificity against related eicosanoids [7]. We, therefore, have developed a MAB against TXB₂ suitable for measurement of TXA₂ at biologically relevant concentrations in conventional fluid RIAs.

2. MATERIALS AND METHODS

2.1. Materials

TXB₂ and other prostanoids were purchased from Sigma (Taufkirchen, FRG). Metabolites of TXB₂ were the generous gift of Dr C.O. Meese (Dr Margarete Fischer-Bosch, Institute of Clinical Pharmacology, Stuttgart, FRG), synthesized according to Fürst [10], Meese et al. [11], Schweer et al. [12], and Meese (in preparation). The radioantigen [5,6,8,9,11,12,14,15(n)-³H]TXB₂ (spec. act. [15(n)-³H]TXB₂ 189 Ci/mmol) and the [³H]TXB₂ assay system (TRK 780) were purchased from Amersham Buchler (Braunschweig, FRG).

2.2. Hybridoma production and selection

Approx. 8-week-old Balb/c mice were immunized each time with 20 µg TXB₂-BSA conjugate according to the method described [7]. Mice showing high titers of TXB₂ binding activity in serum were bled, the spleen removed and the spleen cells fused with the aminopterin sensitive myeloma cell line X63

Correspondence address: M. Reinke, Institut für Pharmakologie und Toxikologie, Universität Erlangen-Nürnberg, Universitätsstraße 22, D-8520 Erlangen, FRG

Table 1

Characteristics of monoclonal antibody against thromboxane B₂ (4E-TBR₁)

Prostaglandins	Crossreaction (IC ₅₀) (%)
TXB ₁	15.7
TXB ₂	100 (0.40 ng)
TXB ₃	39.7
2,3-Dinor TXB ₂	8.6
11-Dehydro-TXB ₁	0.5
11-Dehydro-TXB ₂	0.7
ω -Carboxy-TXB ₂	<0.1
ω -Hydroxy-TXB ₂	<0.1
PGD ₂	<0.1
PGF _{2α}	<0.1
PGE ₂	<0.1
6-Keto-PGF _{1α}	<0.1
Sensitivity (ng)	0.04
Immunoglobulin subclass	IgG2a

Ag8.653 (G. Köhler, MPI, Freiburg, FRG) by the addition of polyethylene glycol 4000 (Merck, Darmstadt, FRG). After isolating hybridoma cells employing a selection medium containing hypoxanthine, aminopterin and thymidine, clones showing TXB₂ binding activity were selected. Subclones were produced on feeder layers of mouse peritoneal macrophages by two cycles of limiting dilution cloning. Cultures were expanded in Dulbecco's modified Eagle medium completed with sodium pyruvate, L-glutamine, 2-mercaptoethanol and 20% of fetal calf serum but without phenol red. The culture supernatants were collected and stored after lyophilization. For further use

1 mg of the lyophilized powder was dissolved in 1 ml of distilled water to prepare a stock solution of MAB.

2.3. Characterization of MAB-TXB₂

The MAB containing culture supernatants were checked for sensitivity and for binding specificity by standard fluid phase RIAs. The total sample volume of 1 ml contained about 10 μ l MAB stock solution (~25% binding). Charcoal (100 μ l of 3% solution) was used to separate the bound and unbound components. RIA with PAB (sensitivity 5 pg/sample) was carried out according to the kit description from Amersham with a sample volume of 300 μ l and 1000 μ l of dextran-coated charcoal used to separate bound from free TXB₂. The Ig subclass was identified using a hybridoma sub-isotyping kit (Calbiochem, Frankfurt, FRG). The MAB was also substituted for PABs in routine assays of the supernatants of macrophages stimulated to release eicosanoids (13) as well as in analysis of blood serum. For the latter experiments 2 ml venous blood was collected every 15 min using an Abbocath-T (20G \times 32 mm, Abbott, Ireland), and directly dropped into tubes containing 100 μ l indomethacin (10⁻⁴ mol/l). After 30 min incubation at 37°C and centrifugation the serum was frozen and stored at -70°C until the measurement of TXB₂ in fluid phase RIA. Platelet aggregation experiments were done with 1 ml platelet rich plasma stimulated by 5 μ l arachidonic acid (76 \times 10⁻³ mol/l) using a whole blood agrometer (Coulter, Krefeld, FRG). Aggregation was measured after addition of MAB-TXB₂ using 2-1000 μ g of the lyophilized culture supernatant.

3. RESULTS

The characteristics of the new MAB-TXB₂ (4E-TBR₁) are compiled in table 1. The MAB belongs to the IgG2a subclass, and the affinity defined by




Fig.1. Standard curves describing the binding of TXB₂ to the MAB-TXB₂ (4E-TBR₁) using phosphate buffered saline alone (●), or supplemented with 10% plasma (○) and 10% serum (□) in a conventional fluid phase RIA.




Fig.2. Recovery of TXB₂ with MAB-TXB₂ (4E-TBR₁) in a conventional fluid phase RIA.

Scatchard analysis is $1.98 \times 10^9 \text{ M}^{-1}$. Employing conventional fluid phase RIA with a 1 ml sample volume, the detection limit of TXB₂ was found to be about 40 pg.

We first examined the crossreactivity of the MAB against known metabolites of TXB₂. Modification of the α -chain usually causes high crossreactivity in PABs. Nevertheless, this MAB shows very low crossreactivity of 8.9% with the important TXB₂ metabolite 2,3-dinor-TXB₂. Reduction of the 5–6 bond to TXB₁ also results in low crossreactivity (15.7%). Upon analyzing metabolites with variations in the ring structure or with alterations in the ω -chain, we found less than 1% crossreactivity in each case. TXB₃ is an exception with a crossreactivity of 39.7%. Crossreactivity with prostaglandins was negligible.

To determine crossreactivity with the biologically active but unstable TXA₂, we tested whether our MAB-TXB₂ interferes with platelet aggregation initiated by arachidonic acid, since it is known that arachidonic acid-induced platelet aggregation is caused by TXA₂ [3]. Concentrations of MAB-TXB₂ which bound more than 55% TXB₂ within the first minute did not interfere with arachidonic acid-induced platelet aggregation in platelet rich plasma. This suggests that there is no prominent crossreactivity with TXA₂.

Some PABs change their sensitivity in assays containing biological fluids. In standard experiments the binding of TXB₂ to the MAB was

not measurably influenced by the addition of up to 10% plasma or serum to the incubation mixture (fig.1). To validate the utility of the new MAB, we tested its accuracy in RIA by adding known amounts of TXB₂. Essentially 100% recovery was found over the tested concentration range (fig.2).

The calcium ionophore A23187 is widely used to investigate the effect of drugs on the production of prostaglandin E₂ and leukotrienes by mouse peritoneal macrophages. We have found this procedure to also produce TXs and have used it to compare our MAB-TXB₂ with a commercial PAB assay system for TXB₂. We examined two drugs, the non-steroidal anti-inflammatory drug indomethacin, an inhibitor of the cyclooxygenase enzyme, and dazmegrel, a selective inhibitor of the TX-synthetase enzyme (fig.3). Both inhibitors were studied at several concentrations. The data obtained from comparing the MAB and the PAB RIA system (see section 2) demonstrate a good correlation between the two RIA results. Both RIAs showed inhibition of the cyclooxygenase enzyme by indomethacin at a concentration of 10^{-6} M and the stepwise loss of inhibition up to a concentration of 10^{-9} M , with a correlation between the two systems of $r = 0.98$. The effect of dazmegrel as blocking agent was demonstrated up to 10^{-7} M , while there was no inhibition at 10^{-8} M . A close correlation of $r = 0.93$ was found for the results with MAB and PAB.

Finally, we examined the effect of ibuprofen, given at 500 mg p.o. to normal volunteers. TXB₂ was present in serum at a concentration of $100 \pm 10 \text{ ng/ml}$. After drug administration TXB₂ declined to $1.0 \pm 0.5 \text{ ng/ml}$ at the time (60–120 min) of peak ibuprofen plasma levels ($n = 3$).

4. DISCUSSION

We have shown that it is possible to produce MABs against TXB₂ which are highly selective in comparison to PABs. TXB₂ metabolites as 2,3-dinor-TXB₂ are less than 10% crossreactive with our MAB. This is in contrast to results with PABs which show considerable crossreactivity with this metabolite (Anhut, personal communication [14], and anti-TXB₂ antibody TRK 780 Amer-sham, assayed in our laboratory). PABs against TXB₂ also show a relatively high degree (up to 13%) of crossreactivity with PGD₂ [14,15],

whereas the MAB-TXB₂ shows less than 0.1% crossreactivity. The ability to detect low amounts of TXB₂ in conventional fluid phase RIAs allows for the substitution of PABs by this MAB-TXB₂ in many assays. This can be advantageous due to the low crossreactivity particularly with respect to chemical substances with a similar ring structure or with a side chain similar to TXB₂. In addition, we have shown that our MAB may be used in routine RIA measurement procedures. Comparing the MAB with a commercial PAB in macrophage experiments we obtained good correlation ($r = 0.96-0.98$). The fact that both antibodies used in fluid phase RIA systems showed differences in the absolute quantities of TXB₂ measured in the tissue culture supernatants did not influence the determination of the inhibition range of the drugs, e.g. IC₅₀. Although differences were observed, they remain within the usual range of statistical error,

possibly caused by the different characteristics of the MAB and the PAB and the different RIA methods. It would be of interest to determine the significance of the differences using independent analytical methods such as GC/MS. Finally, as we are in a position to produce this MAB in almost unlimited quantity and as its characteristics will not change from batch to batch as happens with PABs it may be of use in standardizing experimental results involving the measurement of TX metabolites.

Acknowledgements: We would like to thank Dr I. Otterness (Pfizer Inc., Central Research, Groton, USA) for his support, help and advice. We also thank Dr J. L  thje and Mrs M. Rehm (Institute of Physiological Chemistry, Erlangen) for their support in measurement of platelet aggregation and Mrs E. Yassin for her excellent technical assistance. The work was supported by the Deutsche Forschungsgemeinschaft (La 547/1-1).




Fig.3. Effect of indomethacin and dazmegrel on A23187 (10⁻⁶ M)-stimulated release of TXA₂ (measured in terms of TXB₂-like activity) by mouse peritoneal macrophages using MAB-TXB₂ (4E-TBR₁) and polyclonal antiserum TRK 780 (Amersham) in different fluid phase RIA systems. One representative experiment with 5 culture dishes for each dose.

REFERENCES

- [1] Fitzgerald, D.J., Roy, L., Catella, F. and Fitzgerald, G.A. (1986) *New Engl. J. Med.* 315, 983–989.
- [2] Foegh, M.L., Alijani, M., Helfrich, G.B., Schreiner, G.E. and Ramwell, P.W. (1984) *Transplant. Proc.* 16, 1603–1605.
- [3] Hamberg, M., Svensson, J. and Samuelsson, B. (1975) *Proc. Natl. Acad. Sci. USA* 72, 2994–2998???
- [4] Granström, E., Westlund, P., Kumlin, M. and Nordenström, A. (1985) *Adv. Prostaglandin Thromboxane Leukotriene Res.* 15, 67–70.
- [5] Westlund, P., Granström, E., Kumlin, M. and Nordenström, A. (1986) *Prostaglandins* 31, 929–960.
- [6] Patrono, C., Ciabattini, G., Remuzzi, G., Gotti, E., Bombardieri, S., Di Munno, O., Tartarelli, G., Cinotti, G.A., Simonetti, B.M. and Pieruzzi, A. (1985) *J. Clin. Invest.* 76, 1011–1018.
- [7] Brune, K., Reinke, M., Lanz, R. and Peskar, B.A. (1985) *FEBS Lett.* 186, 46–50.
- [8] David, F., Sommé, G., Provost-Wisner, A., Roth, C., Astoin, M., Dray, F. and Thèze, J. (1985) *Mol. Immunol.* 22, 339–346.
- [9] Tanaka, T., Ito, S., Hiroshima, O., Hayashi, H. and Hayaishi, O. (1985) *BBA* 836, 125–133.
- [10] Fürst, O. (1986) Thesis, University of Stuttgart, FRG.
- [11] Meese, C.O., Fürst, O. and Borstel, B. (1986) *J. Lab. Comp. Radiopharm.* 23, 175–185.
- [12] Schweer, H., Meese, C.O., Fürst, O., Kühl, P.G. and Seybert, H.W. (1988) *Anal. Biochem.*, in press.
- [13] Brune, K., Aehringhaus, U. and Peskar, B.A. (1984) *Agents Actions* 14, 729–734.
- [14] Anhut, H., Bernauer, W. and Peskar, B.A. (1977) *Eur. J. Pharmacol.* 44, 85–88.
- [15] Granström, E., Kindahl, H. and Samuelsson, B. (1976) *Anal. Lett.* 9, 611–627.